Who Paid My Doc
Michelle Hubner
Child & Adolescent Psychiatry Tulsa, OK Medical Doctor
NPI 1770658486 CMS profile 352579
4612 S Harvard Ave, Ste A, Tulsa, OK 74135
General payments
$1,801
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Michelle Hubner of Tulsa, OK is reported in the CMS Open Payments database as having received $1,801 across 138 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 83rd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $250 | 17 | |
| 2019 | General | $1,552 | 121 |
Beside peers
- Michelle Hubner
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Michelle Hubner were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Michelle Hubner | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,552 | $129 | $42–$419 | $163 |
| 2020 | $250 | $81 | $28–$226 | $114 |
| 2021 | $0 | $115 | $31–$326 | $132 |
| 2022 | $0 | $124 | $40–$382 | $149 |
| 2023 | $0 | $130 | $45–$420 | $160 |
| 2024 | $0 | $141 | $42–$490 | $164 |
| 2025 | $0 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
264
Drug cost
$7,239
Branded share of claims
26.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Quetiapine Fumarate Er Quetiapine Fumarate | Brand | 28 | $1,910 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 29 | $1,184 | |
| Lurasidone Hcl | Generic | 24 | $758 | |
| Bupropion Xl Bupropion Hcl | Brand | 13 | $679 | |
| Sertraline Hcl | Generic | 23 | $582 | |
| Quetiapine Fumarate | Generic | 23 | $512 | |
| Lamotrigine | Generic | 17 | $413 | |
| Duloxetine Hcl | Generic | 20 | $355 | |
| Clozapine | Generic | 12 | $230 | |
| Benztropine Mesylate | Generic | 12 | $182 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Records
138 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in Oklahoma
Michelle Holloway
Child & Adolescent Psychiatry · Oklahoma City, OK
Khalil Saliba
Child & Adolescent Psychiatry · Tulsa, OK
Chariny Herring
Child & Adolescent Psychiatry · Tulsa, OK
William Oliva
Child & Adolescent Psychiatry · Spencer, OK
Drew Dawson
Child & Adolescent Psychiatry · Oklahoma City, OK
Geetika Verma
Child & Adolescent Psychiatry · Oklahoma City, OK
Related records
Child & Adolescent Psychiatry in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.